SG10201809955SA - Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer - Google Patents
Method for manufacturing composition comprising local anesthetic, heparinoid, and bufferInfo
- Publication number
- SG10201809955SA SG10201809955SA SG10201809955SA SG10201809955SA SG10201809955SA SG 10201809955S A SG10201809955S A SG 10201809955SA SG 10201809955S A SG10201809955S A SG 10201809955SA SG 10201809955S A SG10201809955S A SG 10201809955SA SG 10201809955S A SG10201809955S A SG 10201809955SA
- Authority
- SG
- Singapore
- Prior art keywords
- heparinoid
- local anesthetic
- buffer
- liquid
- manufacturing composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
METHOD FOR MANUFACTURING COMPOSITION COMPRISING LOCAL ANESTHETIC, HEPARINOID, AND BUFFER An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise: (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) adding a liquid buffer to the heparinoid in solid form or liquid form; (Iv) adding the local anesthetic to the mixture of the liquid buffer and the heparinoid; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 6.8 to about 8.3 is achieved without precipitation of the local anesthetic.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430468P | 2011-01-06 | 2011-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201809955SA true SG10201809955SA (en) | 2018-12-28 |
Family
ID=46457713
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201809955SA SG10201809955SA (en) | 2011-01-06 | 2012-01-05 | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer |
| SG10201402682RA SG10201402682RA (en) | 2011-01-06 | 2012-01-05 | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer |
| SG2013052451A SG191889A1 (en) | 2011-01-06 | 2012-01-05 | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201402682RA SG10201402682RA (en) | 2011-01-06 | 2012-01-05 | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer |
| SG2013052451A SG191889A1 (en) | 2011-01-06 | 2012-01-05 | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140194380A1 (en) |
| EP (2) | EP2661271B1 (en) |
| JP (2) | JP6474193B2 (en) |
| KR (2) | KR20140049964A (en) |
| CN (2) | CN110292639A (en) |
| AU (1) | AU2012204311B2 (en) |
| CA (1) | CA2823949C (en) |
| EA (1) | EA201391014A1 (en) |
| ES (1) | ES2813498T3 (en) |
| HU (1) | HUE051630T2 (en) |
| IL (1) | IL227324A (en) |
| MX (1) | MX359125B (en) |
| SG (3) | SG10201809955SA (en) |
| WO (1) | WO2012094515A1 (en) |
| ZA (1) | ZA201305873B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948154A4 (en) * | 2013-01-28 | 2016-09-14 | Urigen Pharmaceuticals Inc | Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer |
| CN105963244A (en) * | 2016-01-15 | 2016-09-28 | 赵鸣 | Injection artesunate formulation and application thereof |
| MX2019012272A (en) | 2017-04-12 | 2020-07-28 | Urigen Pharmaceuticals Inc | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability. |
| TWI727770B (en) * | 2019-04-26 | 2021-05-11 | 泰宗生物科技股份有限公司 | Pharmaceutical composition for prevention of recurrent urinary tract infection |
| CA3147731A1 (en) * | 2019-07-18 | 2021-01-21 | C. Lowell Parsons | Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002045705A2 (en) * | 2000-12-08 | 2002-06-13 | Pieter Theo Ernst | Regenaration of blood vessels |
| EP2813231A1 (en) * | 2004-01-28 | 2014-12-17 | The Regents of The University of California | Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis |
| US7379623B2 (en) * | 2004-04-30 | 2008-05-27 | Microsoft Corporation | Method to quickly warp a 2-D image using only integer math |
| CN1294994C (en) * | 2004-07-05 | 2007-01-17 | 暨南大学 | Injectable type collagen-based soft tissue filling material and preparation method thereof |
| WO2006007663A1 (en) | 2004-07-22 | 2006-01-26 | Era (Environmental Refrigeration Alternatives) Pty Ltd | Refrigeration system |
| ES2748058T3 (en) * | 2005-01-14 | 2020-03-12 | Urigen Inc | Kits and compositions to treat lower urinary tract disorders |
| WO2007073397A1 (en) | 2005-12-19 | 2007-06-28 | Urigen, Inc. | Kits and improved compositions for treating lower urinary tract discorders |
| ZA200610628B (en) * | 2005-12-19 | 2008-06-25 | Ernst Johanna Catarina | Composition for diagnosing and treating circulatory system diseases |
| US8357795B2 (en) * | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
-
2012
- 2012-01-05 CN CN201910485483.1A patent/CN110292639A/en active Pending
- 2012-01-05 AU AU2012204311A patent/AU2012204311B2/en active Active
- 2012-01-05 KR KR1020137020814A patent/KR20140049964A/en active Search and Examination
- 2012-01-05 HU HUE12732443A patent/HUE051630T2/en unknown
- 2012-01-05 WO PCT/US2012/020357 patent/WO2012094515A1/en active Application Filing
- 2012-01-05 EP EP12732443.2A patent/EP2661271B1/en active Active
- 2012-01-05 EP EP20184392.7A patent/EP3744334A1/en active Pending
- 2012-01-05 CA CA2823949A patent/CA2823949C/en active Active
- 2012-01-05 US US13/978,441 patent/US20140194380A1/en active Pending
- 2012-01-05 CN CN201280011166.2A patent/CN103747790A/en active Pending
- 2012-01-05 SG SG10201809955SA patent/SG10201809955SA/en unknown
- 2012-01-05 JP JP2013548547A patent/JP6474193B2/en active Active
- 2012-01-05 SG SG10201402682RA patent/SG10201402682RA/en unknown
- 2012-01-05 KR KR1020197009012A patent/KR20190049767A/en not_active IP Right Cessation
- 2012-01-05 ES ES12732443T patent/ES2813498T3/en active Active
- 2012-01-05 EA EA201391014A patent/EA201391014A1/en unknown
- 2012-01-05 SG SG2013052451A patent/SG191889A1/en unknown
- 2012-01-05 MX MX2013007975A patent/MX359125B/en active IP Right Grant
-
2013
- 2013-07-04 IL IL227324A patent/IL227324A/en active IP Right Grant
- 2013-08-05 ZA ZA2013/05873A patent/ZA201305873B/en unknown
-
2016
- 2016-11-04 JP JP2016216565A patent/JP2017061503A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140049964A (en) | 2014-04-28 |
| WO2012094515A1 (en) | 2012-07-12 |
| ES2813498T3 (en) | 2021-03-24 |
| IL227324A (en) | 2017-12-31 |
| EP2661271B1 (en) | 2020-07-08 |
| JP2014501782A (en) | 2014-01-23 |
| EP2661271A4 (en) | 2014-09-24 |
| ZA201305873B (en) | 2015-08-26 |
| AU2012204311A1 (en) | 2013-08-22 |
| KR20190049767A (en) | 2019-05-09 |
| JP2017061503A (en) | 2017-03-30 |
| EP2661271A1 (en) | 2013-11-13 |
| US20140194380A1 (en) | 2014-07-10 |
| AU2012204311B2 (en) | 2017-05-04 |
| CN103747790A (en) | 2014-04-23 |
| CA2823949C (en) | 2020-09-22 |
| EA201391014A1 (en) | 2014-01-30 |
| EP3744334A1 (en) | 2020-12-02 |
| MX359125B (en) | 2018-09-13 |
| SG10201402682RA (en) | 2014-08-28 |
| IL227324A0 (en) | 2013-09-30 |
| MX2013007975A (en) | 2014-02-27 |
| CA2823949A1 (en) | 2012-07-12 |
| HUE051630T2 (en) | 2021-03-01 |
| CN110292639A (en) | 2019-10-01 |
| SG191889A1 (en) | 2013-08-30 |
| JP6474193B2 (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX2011010908A (en) | Anti-tnf-î± antibodies and their uses. | |
| UA90048C2 (en) | Conditioned blood composition and method for its production | |
| TN2011000416A1 (en) | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient | |
| EP2576578A4 (en) | Polymorphs of 2'-o-fucosyllactose and producing thereof | |
| EP4324479A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| MY152033A (en) | Anti-siglec-15 antibody | |
| MY158504A (en) | Fatty acid niacin conjugates and their uses | |
| MX2019000547A (en) | Stabilized liquid and lyophilized adamts13 formulations. | |
| EA031157B9 (en) | Orally administered corticosteroid composition | |
| NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| SG10201809955SA (en) | Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer | |
| EP2328550A4 (en) | Mucoadherents compositions and their use | |
| MY161430A (en) | A method for producing a composition of meloxicam | |
| AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
| WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| MX2012000954A (en) | Pharmaceutical compositions. | |
| MX2015009696A (en) | Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer. | |
| MX2012007234A (en) | Calcipotriol monohydrate nanocrystals. | |
| SG179069A1 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| PT2454266E (en) | 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt | |
| UA111145C2 (en) | Pharmaceutical composition |